Latest Conference Coverage

REGENXBIO Reports Positive Phase 1/2 Data for Higher Dose of RGX-202 in Duchenne Muscular Dystrophy

Reactivating Muscle Stem Cells in DMD: The Science Behind SAT-3247

Phil Lambert, PhD, chief scientific officer at Satellos Bioscience, discusses the rationale and early clinical progress of SAT-3247, a novel regenerative therapy targeting muscle stem cells in Duchenne muscular dystrophy.

Addressing Social Isolation and Feelings of Loneliness in Patients With MS: Tiffany Malone, MSW, MSCS

The director of the John A. Schafer, MD Multiple Sclerosis Achievement Center at Dignity Health highlighted the significant impact of loneliness in individuals with multiple sclerosis. [WATCH TIME: 6 minutes]

Emerging Biomarkers for Monitoring Remyelination in Multiple Sclerosis: Ahmed Abdelhak, MD

The assistant professor of neurology at the University of California, San Francisco discussed current advancements and ongoing challenges in identifying biomarkers to accurately monitor remyelination in MS clinical trials. [WATCH TIME: 5 minutes]

Evaluating Risk: Clarifying the Safety Data Behind Efgartigimod

Josh Bryson, PhD, head of Medical Affairs at Argenx, discussed the safety profile of efgartigimod in light of recent FAERS-based infection data and offered clinical context for patient care.

A Case-Based Overview of Treatment Strategies for Relapse Prevention in MOGAD: Smathorn Thakolwiboon, MD

The assistant professor of neurology at Mayo Clinic College of Medicine and Science outlined a case of myelin oligodendrocyte glycoprotein antibody-associated disease from diagnosis to long-term management. [WATCH TIME: 5 minutes]

NeuroVoices: Kathy Zackowski, PhD, OTR, on Promoting Psychosocial Wellness Research in MS Care

The associate vice president of research at National MS Society talked about the need for evidence-based wellness strategies in multiple sclerosis, particularly focusing on psychosocial interventions.

Meta-Analysis Reveals Cognitive Behavioral Therapy Ineffective for MS-Related Fatigue

Findings from a late-breaking poster presented at CMSC 2025 suggest that CBT does not improve fatigue severity or impact in patients with multiple sclerosis.

Individualizing Disease-Modifying Therapy Selection in Newly Diagnosed MS: Gabrielle Macaron, MD

The assistant professor in the Department of Neuroscience at Université de Montréal discussed key clinical factors influencing DMT selection in patients newly diagnosed with multiple sclerosis. [WATCH TIME: 5 minutes]

OPTIMUM Phase 3 Extension Further Highlights Sustained Efficacy, Safety of Ponesimod

New long-term data reveals ponesimod's effectiveness in reducing relapses and MRI lesions in relapsing multiple sclerosis patients, ensuring safety over 8.2 years.

Neurologists Support DMT Use in Older Patients With Multiple Sclerosis, Survey Shows

Neurologists advocate for personalized treatment approaches in older MS patients, emphasizing the importance of individual assessment over age-based rules for DMT discontinuation.

Treatment and Diagnosis of MOG-Associated Disorders in Pediatric vs Adult: E. Ann Yeh, MD

The professor of pediatrics in neurology at the University of Toronto discussed differences in disease course, treatment strategy, and trial challenges of MOG-associated disorders in pediatric versus adult patients. [WATCH TIME: 5 minutes]

BTK Inhibitor Fenebrutinib Demonstrates Long-Term Suppression of MS Activity in Open-Label Extension

Fenebrutinib shows promising results in reducing relapse rates and disability progression in relapsing multiple sclerosis patients over two years.

Hypertension Awareness Gaps in Patients With Multiple Sclerosis: Michael Robers, MD, MS

The assistant professor of neurology at Barrow Neurological Institute talked about the lack of public awareness for hypertension among individuals with MS despite many meeting diagnostic criteria. [WATCH TIME: 6 minutes]

Wearing Off Rates Higher in Ocrelizumab Than Ofatumumab, Study Suggests

MS Therapy Cladribine Remains Effective in Patients With Suboptimal Response to Prior Injectable DMT

Cladribine shows promising results in reducing relapse rates for patients with relapsing multiple sclerosis after inadequate response to injectable therapies.

Starting Comprehensive Multiple Sclerosis Care at Initial Diagnosis: Mary R. Rensel, MD, FAAN, ABIHM

The associate professor of medicine at the Cleveland Clinic Lerner College of Medicine highlighted the importance of early, multidisciplinary intervention for patients with multiple sclerosis. [WATCH TIME: 3 minutes]

CMSC Live: 2025 Annual Meeting Day 3

Host Jeffrey Wilken, PhD, chats with Riley Bove, MD, about the third day of the 2025 CMSC Annual Meeting in Phoenix, Arizona.

Pregnancy Outcomes in Ofatumumab-Treated Women Appear Consistent With General Population Rates

A newly presented analysis of data from the Novartis Global Safety Database and the PRIM study assessed pregnancy and infant outcomes in women with multiple sclerosis treated with ofatumumab.

Identifying and Treating Progression in MS Beyond Relapses: Celia Oreja-Guevara, MD, PhD

The vice chair of neurology at the Hospital Clínico San Carlos in Madrid highlighted the growing importance of detecting and managing progression in multiple sclerosis, particularly PIRA. [WATCH TIME: 6 minutes]

Fumarates Lead to Lower Infection-Related Healthcare Resource Utilization Relative to Anti-CD20s

A study reveals long-term fumarate therapy significantly reduces infection-related healthcare utilization in multiple sclerosis patients compared to anti-CD20 treatments.

CMSC Live: 2025 Annual Meeting Day 2

Host Jeffrey Wilken, PhD, chats with Anthony Feinstein, MPhil, PhD, FRCP, about the second day of the 2025 CMSC Annual Meeting in Phoenix, Arizona.

Survey Results Point to High Rates of Burnout Among APPs and Pharmacists in Neurology

A new survey presented at CMSC 2025 highlighted the prevalence of burnout and job-related stress among neurology-based advanced practice providers and clinical pharmacists in the United States.

Rebound Effect Not Observed With Multiple Sclerosis Therapy Ozanimod

New findings reveal ozanimod shows no significant rebound effect in relapsing MS patients after treatment discontinuation, ensuring safer transitions.

Single-Center Study Provides Support for Natalizumab Use in Pregnant Women With Multiple Sclerosis

Research highlights the benefits of natalizumab during pregnancy for women with multiple sclerosis, showing reduced disease activity and improved outcomes.

CMSC Poster Gives Demographic Insights for Phase 3 PERSEUS Study of Tolebrutinib

The ongoing PERSEUS trial explores tolebrutinib's potential as a treatment for primary progressive multiple sclerosis, with results anticipated soon.

Two-Year CHIMES Study Data Highlight Effect of Ocrelizumab in Diverse Relapsing MS Patient Population

New findings reveal ocrelizumab significantly improves symptoms, cognition, and fatigue in Black and Hispanic patients with relapsing multiple sclerosis.

NeuroVoices: Elisabeth Sonesson, PhD, on Imlifidase’s Targeted, Fast-Acting Approach to GBS

The vice president and franchise lead of Autoimmune at Hansa Biopharma shed insights on imlifidase’s targeted mechanism and promising phase 2 data in treating Guillain-Barré syndrome.

Overviewing Phase 2 Data of Imlifidase in Guillain-Barré Syndrome: Elisabeth Sonesson, PhD

The vice president and franchise lead of Autoimmune at Hansa Biopharma provided clinical insights on latest phase 2 safety and efficacy data on imlifidase, an IgG-cleaving antibody, in Guillain-Barré syndrome. [WATCH TIME: 3 minutes]

Abstracts for the 2025 CMSC Annual Meeting Are Now Live!

The 39th CMSC Annual Meeting is set to be held May 28-31, 2025, in Phoenix, Arizona. The International Journal of MS Care has published the abstracts.